Aimin Song

Aimin Song

Auto-generated profile, based on publicly available information

Aimin Song

Department of Peptide Therapeutics, Genentech, South San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 November 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
IKIvy Kekessie
Ivy Kekessie
TGTatiana Goncharov
Tatiana Goncharov
LKLászló G. Kőműves
László G. Kőműves
DVDomagoj Vucic
Domagoj Vucic
ASAimin Song
Aimin Song

18 January 2024 in Bioconjugate Chemistry
Verified
Journal Article
Open access
LPLingling Peng
Lingling Peng
EHElizabeth Helgason
Elizabeth Helgason
RMRafael Miranda
Rafael Miranda
JTJeffrey Tom
Jeffrey Tom
JZJennifer Zhang
Jennifer Zhang
ASAimin Song
Aimin Song
N-Boc-N-(2-(tritylthio)ethoxy)glycine has been developed as a building block for peptide ubiquitination, which is fully compatible with solid-phase Fmoc chemistry and common peptide modifications including phosphorylation, methylation, acetylation, biotinylation, and fluorescence labeling. The optimal conditions for peptide cleavage and auxiliary removal were obtained. The utility of this building block in peptide ubiquitination was demonstrated by the synthesis of seven ubiquitinated histone and Tau peptides bearing various modifications. Cys residues were well tolerated and did not require orthogonal protection. The structural integrity and folding of the synthesized ubiquitinated peptides were confirmed by enzymatic deubiquitination of a fluorescently labeled ubiquitin conjugate. The synthetic strategy using this building block provides a practical approach for the preparation of ubiquitinated peptides with diverse modifications.

10 September 2026 in Science
Verified
Journal Article
Closed access
MSMonica Sharma
Monica Sharma
ZKZachary B. Katz
Zachary B. Katz
DDDavid C. Dewitt
David C. Dewitt
KRKiersten M. Ruff
Kiersten M. Ruff
ASAkashdip Singh
Akashdip Singh
ASAndrey S. Shaw
Andrey S. Shaw
T cell receptor (TCR) engagement stimulates formation of a biomolecular condensate, including the scaffold protein linker of activated T cells (LAT). We investigated whether the immune-inhibitory receptor programmed cell death protein 1 (PD-1) inhibits by impeding TCR-induced LAT condensation. In vitro reconstitutions revealed that the cytoplasmic domain of PD-1 directly inhibited LAT condensation. This inhibitory interaction required tyrosine residues in the two inhibitory motifs of PD-1. Contrary to current working models, tyrosine phosphorylation eliminated PD-1 inhibition. Replacing tyrosine with tryptophan reconstituted PD-1 inhibition in T cells, confirming that phosphorylation does not mediate this effect. These findings support the concept that hydrogen bond–donating aromatic residues within inhibitory motifs provide the primary mechanism that explains how inhibitory receptors disrupt signaling networks and block immune activation.

9 June 2026 in Journal of Molecular Biology
Verified
Journal Article
Open access
WTWanjian Tang
Wanjian Tang
MUMark Ultsch
Mark Ultsch
EAEmel Adaligil
Emel Adaligil
BTBenjamin Tombling
Benjamin Tombling
SFSteven Fleming
Steven Fleming
DKDaniel Kirchhofer
Daniel Kirchhofer
Neutrophil serine protease 4 (NSP4) is the most ancient member of the NSP family, which includes neutrophil elastase, proteinase 3 and cathepsin G, but is unique in its strong preference for cleavage after an arginine residue. NSP4 is highly expressed in myeloid precursor cells and regulates the levels of vasoactive histamine during mast cell maturation. Neutrophils store active NSP4 in azurophilic granules, but its function in neutrophil biology remains unknown. To advance the understanding of NSP4's biological role, we aimed to generate potent and selective inhibitors by using large mRNA-displayed libraries each encoding up to 1013 unique macrocyclic peptides (MCPs) containing both natural and non-natural amino acids. Library screening yielded six MCPs, which strongly inhibited the activity of recombinant and endogenous cell-derived NSP4, but did not inhibit 13 structurally related proteases. In agreement with biochemical studies with activity-based probes, crystal structures of the two most potent inhibitors MCP-3 and MCP-4 (KD = 6.5 nM and 1.0 nM, respectively) revealed that these MCPs bind to the NSP4 active site region. Remarkably, the two MCPs resembled the plant-derived sunflower trypsin inhibitor-1 in respect to ring conformation, substrate-like interaction with the active site and resistance to hydrolysis. Therefore, these de novo generated MCPs recapitulated the standard mechanism used by natural serine protease inhibitors. This study highlights the power of mRNA-display technology to generate potent and highly selective protease inhibitors, such as the macrocyclic NSP4 inhibitors identified in this work, which serve as valuable tools to study the biological functions of this elusive protease.

9 February 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FCFei Cai
Fei Cai
LZLijuan Zhou
Lijuan Zhou
BDBryce D. Delgado
Bryce D. Delgado
WCWenping Chang
Wenping Chang
JTJeffrey Tom
Jeffrey Tom
YZYingnan Zhang
Yingnan Zhang
Background/Objectives: Nature has evolved millions of venom-derived peptides with diverse biological functions, a substantial fraction of which target complex membrane proteins such as G-protein-coupled receptors and ion channels. Many of these peptides are stabilized by multiple disulfide bonds, endowing them with exceptional structural stability and favorable pharmacological properties. Methods: Leveraging this natural diversity, we developed a robust venom peptide therapeutics discovery system built on phage display technology and constructed a library using approximately 482 venom-derived scaffolds. The library design was guided by a machine learning (ML) model capable of predicting mutation-tolerant residues that preserve peptide foldability, maximizing structural integrity and sequence diversity. Results: The resulting VCX library was evaluated through screening against four diverse targets (CD47, DLL3, IL33, and P2X7R), yielding strong binders for all four, a success rate of 100%. Furthermore, by integrating high-throughput recombinant expression of thioredoxin–venom fusion proteins along with ML-assisted affinity maturation, we rapidly identified potential leads for DLL3 binders. Conclusions: This venom-based discovery platform offers significant advantages in both functionality and developability compared with conventional peptide discovery approaches. By combining natural structural diversity, ML-guided design, and recombinant expression, it enables efficient identification of “antibody-like” binders with molecular weights much smaller than those of antibodies. Consequently, it provides a powerful strategy for developing next-generation peptide therapeutics targeting challenging protein–protein interactions and complex membrane proteins.